Published in final edited form as:

Bioorg Med Chem. 2007 June 15; 15(12): 4106–4112. doi:10.1016/j.bmc.2007.03.076.

***In-vitro* Investigation of Oxazol and Urea Analogues of Morphinan at Opioid Receptors**

Xuemei Peng^a, Brian I. Knapp^b, Jean M. Bidlack^b, and John L. Neumeyer^{a,*}

^a Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478

^b Department of Pharmacology and Physiology, School of Medicine and Dentistry, University of Rochester, Rochester, New York 14642

Abstract

A series of 2-amino-oxazole (**7** & **8**) analogs and 2-one-oxazole analogs (**9** & **10**) were synthesized from cyclorphan (**1**) or butorphan (**2**) and evaluated *in-vitro* by their binding affinity at μ , δ and κ opioid receptors and compared with their 2-aminothiozole analogs **5** & **6**. Ligands **7–10** showed decreased affinities at κ and μ receptors.

Urea analogues (**11–14**) were also prepared from 2-aminocyclorphan (**3**) or 2-aminobutorphan (**4**) and evaluated *in-vitro* by their binding affinity at μ , δ and κ opioid receptors. The urea derived opioids retained their affinities at μ receptors while showing increased affinities at δ receptors and decreased affinities at κ receptors. Functional activities of these compounds were measured in the [³⁵S] GTP γ S binding assay, illustrating that all of these ligands were κ agonists. At the μ receptor, compounds **11** and **12** were μ agonist/antagonists.

Keywords

Morphinan; Urea; Oxazol; Opioid

1. Introduction

Opioid receptors (μ , κ and δ) are distributed throughout the central and peripheral nervous system and are involved in a variety of physiological processes, especially analgesia.^{1–3} Opioids bind to specific neuronally located proteins and initiate physiological responses. It is generally accepted that the phenol moiety is necessary for narcotic analgesic binding to its receptors.⁴ The phenolic hydroxyl group is recognized as a requisite for the formation of a hydrogen bond with a dipolar site on the receptor and for good antinociceptive activity. Interest in investigating the 3-position was driven by our desire to identify replacements of the 3-OH group of morphinans, which like many opioid-receptor interactive agents, is prone to metabolic inactivation resulting in low oral bioavailability and short duration of action. An approach to improving the pharmacological properties of analgesics such as morphine is to modify the phenolic hydroxy function.

*Corresponding author. Tel: +1-617-855-3388; fax: +1-617-855-3388, Email: E-mail: Neumeyer@mclean.harvard.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Previous reports from our laboratories demonstrated that the replacement of the 3-OH of cyclorphan (**1**) or butorphan (**2**) with 2-aminothiozole as in compounds **5** and **6**. Compounds **5** or **6** resulted in sustained high affinity binding to opioid receptors (Figure 1).^{5–6} Our investigations extended these earlier observations by the replacement of the phenolic hydroxyl moiety with 2-aminooxazole (**7** & **8**) and 2-one-oxazole (**9** & **10**) incorporated into cyclorphan (**1**) and butorphan (**2**).

In continuing these studies on the development of effective analgesics, and the development of pharmaceutical agents for cocaine abuse, we focused our interests on the structural modification and pharmacological evaluation of analogues of cyclorphan and butorphan, which were known to possess mixed κ agonist and μ agonist/antagonist pharmacological profiles.^{7–8} We also wish to examine the effect of substitution of the 3-OH group with a series of urea analogues (**11–14**). The urea group was introduced since the substitution of oxygen for nitrogen increases the ability to interact at opioid receptors by the formation of hydrogen bonds.⁹ Ideally, these modified compounds would have a longer duration of action and better bioavailability.

2. Results and discussion

2.1 Chemistry

The levoratory morphinans (**1**, **2**) were prepared from commercially available (–)-3-hydroxy-N-methylmorphinan tartrate (levorphanol) which was converted to the free base, and N-demethylated¹⁰ to yield the normorphinan, followed by alkylation with cyclobutylmethyl(or cyclopropylmethyl) bromide and characterized as their crystalline mandelate salts (**1** and **2**) respectively. As shown in Scheme 1, the oxazole analogues of morphinans were made by first treating morphinans with $\text{HNO}_3/\text{CH}_3\text{COOH}$ to give a 2-nitro-3-hydroxymorphinan **15** and **16**. The nitrated morphinans were reduced (Pd/C , H_2) to give 2-amino-3-hydroxymorphinans **17** and **18**, which without further purification, were cyclized with di(imadazole-1-yl)methanimine¹¹ to give the oxazols **7** and **8**.¹² A similar strategy was used to prepare the oxazole-one derived morphinans **9** & **10**. Upon cyclization of **17** and **18** with 1, 1'-carbonyl-diimidazole, the amino-oxazoles **9** and **10** were obtained in moderate yields.¹³

After triflation of the phenols (**1** & **2**), the corresponding triflates were subjected to palladium-catalyzed amination yielding the amines **3** and **4** in moderate yields.^{5–6} The mono substituted urea targets **11** and **12** were made in 59–63% yield by treating **3** and **4** with KNCO in acetic acid.⁹ The N-methyl ureas **13** and **14** were made in yields ranging 66–78% by treating **3** and **4** with the corresponding commercially available methyl isocyanate.

2.2 Pharmacological Results and Discussion

2.2.1 Affinity and Selectivity of the Synthesized Ligands—All the novel morphinan ligands were evaluated for their affinity at and selectivity for μ , δ and κ opioid receptors with Chinese hamster ovary (CHO) cell membranes stably expressing the human opioid receptors. The data are summarized in Table 1. For comparison purposes, opioid binding affinity data for cyclorphan (**1**), butorphan (**2**), 3-aminocyclorphan (**3**), 3-aminobutorphan (**4**) and 2-aminothiozole compounds (**5** & **6**) are also included.

Previous reports from our laboratories indicated that 2-aminothiazole-derived morphinans (**5** & **6**) possess high affinity and selectivity at the κ receptor. Our synthetic studies extended these earlier observations by incorporating 2-amino-oxazole and 2-one-oxazole into cyclorphan (**1**) and butorphan (**2**). Compared to the 2-aminothiozole analogs (**5** & **6**), it was unexpected to find that a remarkable decrease of affinity at μ and at κ receptors was observed in 2-amino-oxazole (**7** & **8**) and oxazole-2-one analogs (**9** & **10**), especially with N-cyclopropylmethyl morphinan analogs (**7** and **9**). Compounds **7**, **8** and **9** showed 18%–46% inhibition at δ receptor

at 10 nM. It is apparent that there is a binding pocket at the 3-hydroxy position for both μ and κ receptors. Although the 2-amino-oxazole moiety cannot be considered as a bioisosteric replacement of the phenol group, it can be viewed as an extension of the aromatic functionality of the molecule. And the 2-one oxazol analogs can be considered as a tautomeric form of 2-hydroxy oxazol (**19**, Figure 2). We expected that the 2-amino and 2-hydroxy group may effectively substitute the phenolic hydroxyl group to form a presumed hydrogen bond on its receptor binding site, which may result in improved pharmacological properties.

The 3-D structures may explain the reason why compounds (**7–10**) possess low affinities at opioid receptors. As shown in Figure 3, the 2-amino-oxazole ring of compound **7** (Fig. 3A) has a different orientation to the 2-aminothiozole compound (**5**, Fig. 3B). The orientation of the 2-amino group appears to be important for forming a hydrogen bond on its receptor binding site.

The receptor binding affinities of the urea derivatives (**11–14**) were evaluated. From the data shown in Table 1, it is noteworthy that the mono substituted urea analogs **11** and **12** retained the same affinity at the μ receptor, and a 3~5 fold decrease at κ and a 6.5 fold increase at δ for **11** were observed when compared with 3-aminocyclorphan (**3**) and 3-aminobutorphan (**4**). The binding affinities of the methyl urea derived opioids (**13** and **14**) at all three receptors were generally lower than the binding affinities of the amino precursors (**3** and **4**).

2.2.2 Efficacy Assay of Selected Ligands—To characterize the relative efficacy of these morphinan ligands, compounds cyclorphan (**1**) and butorphan (**2**) were selected for the [35 S]GTP γ S assay. Table 2 shows the pharmacological properties of these ligands in stimulating [35 S]GTP γ S binding mediated by the κ opioid receptor.

Ligands **11**, **12** and **13** produced maximal stimulation of [35 S]GTP γ S binding ($E_{\max}$) comparable to that of the monomers **1** and **2**, but less than that of selective agonist U50,488. The EC_{50} values of these ligands are higher than monomers, similar to U50,488. Similar to the parent compound cyclorphan (**1**) and butorphan (**2**), all of these ligands did not inhibit U50,488-stimulated [35 S]GTP γ S, which suggested that all of these ligands were full κ selective agonists.

The agonist and antagonist properties of these ligands in stimulating [35 S]GTP γ S binding mediated by the μ opioid receptor are shown in Table 3.

Ligands **11** and **12** produced low maximal stimulation of [35 S]GTP γ S binding mediated by μ receptor comparable to that of the parent compound cyclorphan (**1**) and butorphan (**2**). They also produced the highest maximal inhibition ($I_{\max}$) of the DAMGO stimulated [35 S]GTP γ S binding indicating that ligand **11** and **12** are μ antagonists/agonists.

The preliminary assay for agonist and antagonist properties of these ligands in stimulating [35 S]GTP γ S binding mediated by the κ opioid receptor illustrated that compounds **11**, **12** and **13** were κ agonists, however compounds **11** and **12** were μ agonist/antagonist.

3. Conclusions

A series of 2-amino-oxazole analogs (**7 & 8**) and 2-one-oxazole analogs (**9 & 10**) were synthesized from cyclorphan (**1**) or butorphan (**2**) and evaluated *in-vitro* by their binding affinity at μ , δ and κ opioid receptors. These series opioids showed decreased affinities at κ and μ receptors. Compounds **7**, **8** and **9** showed inhibition at δ receptors. The orientation of the 2'-amino group appears to be important criteria for forming hydrogen bonds on its receptor binding site.

A series of urea analogues were synthesized from 2-aminocyclophorphan (**3**) or 2-aminobutorphan (**4**) and evaluated *in-vitro* by their binding affinity at μ , δ and κ opioid receptors. The urea derived opioids retained their affinities at μ receptors while showing increased affinities at δ receptors and decreased affinities at κ receptors. Such urea derivatives may be useful for the potential development of longer-acting analgesics as well as medications for drug abuse. Functional activities of these compounds were measured in the [^{35}S]GTP γ S binding assay, indicating that ligands **11**, **12** and **13** were κ agonists while, compounds **11** and **12** were μ agonist/antagonists.

4. Experimental

4.1 Chemical syntheses

Melting points were determined on a Thomas-Hoover capillary tube apparatus and are reported uncorrected. ^1H and ^{13}C NMR spectra were recorded on a Bruker AC300 spectrometer using tetramethylsilane as an internal reference. Element analyses, performed by Atlantic Microlabs, Atlanta, GA, were within 0.4% of theoretical values. Analytical thin-layer chromatography (TLC) was carried out on 0.2 mm Kieselgel 60F 254 silica gel plastic sheets (EM Science, Newark). Flash chromatography was used for the routine purification of reaction products. The column output was monitored by TLC.

4.1.1 2-nitro-3-hydroxyl -N- cyclopropylmethylmorphinan (15)—To a solution of cyclophorphan **1** (300 mg) in 5 mL formic acid was added a solution of 0.2 mL nitric acid in 2 mL of formic acid slowly. The mixture was stirred at room temperature overnight. It was basified with saturated sodium bicarbonate and extracted with methylene chloride. The combined organic extracts were washed with brine and concentrated. The residue was chromatographed eluting with EtOAc: Et $_3$ N=100:1 to give 190 mg (62.3%) compound **15** as yellow solid. ^1H NMR(300Hz, CDCl $_3$): 7.83(s, 1H), 7.06(s, 1H), 3.14-3.12(m, 1H), 3.00(d, J =18.0Hz, 1H), 2.77-2.72(m, 1H), 2.66(dd, J =18.0Hz, 5.7Hz, 1H), 2.52(dd, J =6.3Hz, 12.6Hz, 1H), 2.37-2.28(m, 2H), 2.06-0.83(m, 13H), 0.53-0.50(m, 2H), 0.12-0.09(m, 2H). ^{13}C NMR(75Hz, CDCl $_3$): 153.9, 153.3, 131.4, 130.6, 123.0, 116.3, 59.9, 55.2, 45.3, 44.5, 41.8, 38.9, 36.6, 27.1, 26.3, 23.7, 22.2, 9.3, 4.0, 3.6.

4.1.2. 2-amino-3-hydroxyl -N- cyclopropylmethylmorphinan (17)—A mixture of (200mg, 0.66mmol, **15**) 2-nitro-3-hydroxyl -N- cyclopropylmethylmorphinan, (420mg, 6.6mmol) of ammonium formate and (200 mg) of Pd/C(10% w/w) in 25 mL of methanol was stirred at room temperature overnight. The catalyst was filtered of and the filtrate was concentrated to yield 160 mg of the desired compound **16**, which was used for the next step without further purification. ^1H NMR(300Hz, CD $_3$ OD): 6.54(s, 1H), 6.46(s, 1H), 3.18 (s, 1H), 2.82-0.91 (m, 18 H), 0.48(d, J =8.1 Hz, 2H), 0.12(d, J = 4.8 Hz, 2H). ^{13}C NMR(75Hz, CD $_3$ OD): 144.2, 132.9, 130.1, 127.6, 115.0, 111.9, 59.2, 55.8, 50.2, 45.9, 43.7, 40.9, 36.6, 36.3, 26.5, 26.3, 23.9, 22.0, 8.1, 4.0, 3.9.

4.1.3. 2'-Amino oxazole[5,4-*b*]-N- cyclopropylmethylmorphinan (7)—A solution containing di(imidazole-1-yl)methanimine (91.2 mg) and N-2-amino-3-hydroxyl-cyclopropylmethylmorphinan **17** (47.1mg) in anhydrous THF (10ml) was allowed to reflux under nitrogen overnight. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (20mL), and washed successively with water, saturated aqueous NH $_4$ Cl solution and brine. The organic layer was dried over MgSO $_4$, filtered and concentrated *in vacuo* to afford the crude product. Further purification by silica gel chromatography gave the desired product as a yellow solid **7** (Yield 37.5%). Mp. 125–128°C. ^1H NMR (300Hz, CDCl $_3$): 7.16(s, 1H), 7.06(s, 1H), 5.36(s, 2H), 3.11-2.98(m, 2H), 2.75-0.84(m, 17H), 0.52(dd, J =8.1Hz, 1.2Hz, 2H), 0.13-0.07(m, 2H). ^{13}C NMR(75Hz, CDCl $_3$): 161.9, 148.0, 140.3, 134.0,

133.5, 114.8, 105.3, 60.0, 55.8, 45.7, 45.2, 42.3, 37.9, 37.1, 26.8, 26.6, 25.0, 22.1, 9.4, 4.0, 3.6. Anal. Calcd(C₂₁H₂₇N₃·O·0.8H₂O): C 71.68, H 8.19, N 11.94. Found: C 71.69, H 8.08, N 11.46.

4.1.4. 2-Nitro-3-hydroxyl -N- cyclobutylmethylmorphinan (16)—This reaction was carried out with butorphan. The compound was obtained as a yellow solid (yield: 25.1%) ¹HNMR(300Hz, CDCl₃): 7.84(s, 1H), 7.05(s, 1H), 3.06-2.99(m, 1H), 2.87-2.84(m, 2H), 2.61-0.99(m, 2H). ¹³CNMR(75Hz, CDCl₃): 154.0, 153.3, 131.4, 130.8, 123.0, 116.2, 61.4, 55.4, 45.4, 44.6, 41.9, 38.9, 36.6, 34.7, 27.7, 27.1, 26.3, 23.9, 22.2, 18.8

4.1.5. 2-Amino-3-hydroxy-N- cyclobutylmethylmorphinan (18)—The compound was obtained as light-brown solid. (yield 94.0%). ¹HNMR(300Hz, CDCl₃): 6.50(d, *J*=6.6Hz, 2H), 3.47(s, 1H), 2.57(s, 2H), 2.53-2.18(m, 5H), 2.11-1.87(m, 4H), 1.84-1.57(m, 7H), 1.38-1.15(m, 6H). ¹³CNMR(75Hz, CDCl₃): 144.0, 132.9, 130.5, 128.5, 115.2, 112.0, 61.2, 55.8, 46.1, 44.2, 41.4, 36.6, 34.3, 28.2, 28.1, 26.7, 26.5, 24.0, 22.1, 18.8

4.1.6. 2'-Amino oxazole[5,4-*b*]-N- cyclobutylmethylmorphinan (8)—Yellow solid (Yield 38.6 %). Mp. 165–166°C. ¹HNMR(300Hz, CDCl₃): 7.15(s, 1H), 7.08(s, 1H), 5.49(s, 2H), 3.10(d, *J*=18Hz, 1H), 2.83-0.83(m, 24H). ¹³CNMR(75Hz, CDCl₃): 161.7, 148.1, 140.4, 134.2, 133.7, 115.0, 105.3, 61.5, 56.0, 45.8, 45.2, 42.4, 37.8, 37.1, 35.0, 31.6, 27.9, 26.8, 26.6, 25.2, 22.6, 18.8. Anal. Calcd (C₂₂H₂₉N₃O·0.4H₂O): C 73.67, H 8.37, N 11.71. Found: C 73.83, H 8.33, N 11.32.

4.1.7. Oxazole-2-one-N- cyclopropylmethylmorphinan (9)—A solution containing 1,1'-carbonyl-diimidazole (113.6mg, 0.70mmol) and N-2-amino-3-hydroxyl-cyclopropylmethylmorphinan (0.58mmol) in anhydrous THF (10ml) was allowed to reflux under nitrogen overnight. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (20mL), and washed successively with water, saturated aqueous NH₄Cl solution and brine. The organic layer was dried over MgSO₄, filtered and concentrated *in vacuo* to afford the crude product. Further purification by silica gel gave the desired product as a light yellow foam-solid **9** (Yield 50.6%). Mp. 125–128°C. ¹HNMR(300Hz, CDCl₃): 7.09(s, 1H), 6.79(s, 1H), 3.22(s, 1H), 3.01(d, *J*=18.3Hz, 1H), 2.83-0.88(m, 17H), 0.54(d, *J*=8.1Hz, 2H), 0.15-0.13(m, 2H). ¹³CNMR(75Hz, CDCl₃): 156.6, 143.5, 134.4, 132.9, 128.4, 108.5, 106.4, 59.5, 55.4, 45.4, 44.3, 41.4, 37.7, 36.7, 26.6, 26.4, 25.0, 21.9, 8.8, 4.0, 3.7. Anal. Calcd (C₂₁H₂₆N₂O₂·0.2H₂O): C 73.74, H 7.78, N 8.19. Found: C 73.85, H 7.79, N 7.94.

4.1.8. Oxazole-2-one-N- cyclobutylmethylmorphinan (10)—Light yellow foam-solid (Yield 50.6%). ¹HNMR(300Hz, CDCl₃): 7.16(s, 1H), 7.06(s, 1H), 5.36(s, 2H), 3.11-2.98(m, 2H), 2.75-0.84(m, 21H). Anal. Calcd (C₂₂H₂₈N₂O₂·0.2H₂O): C 74.21, H 8.04, N 7.87. Found: C 73.92, H 7.82, N 7.60.

4.1.9. N- cyclopropylmethylmorphinan-3-amino-urea (11)—A solution of 3-amino-N-cyclopropylmethylmorphinan **3** (100 mg) in acetic acid (1 mL) was treated with a solution of potassium cyanate (40 mg) in water (1mL). After brief heating on the oil bath, the resulting mixture was evaporated and the residue was dissolved in 5% NaOH, exacted with EtOAc. The extract was combined and washed with brine, evaporated to yield a yellow oil. The crude product was purified by column chromatography (SiO₂, EtOAc: Hexane: Et₃N=50: 50:1) to yield a product as white foam **5** (Yield 59.0 %). Mp. 112–115°C. ¹HNMR(300Hz, CDCl₃): 7.7(s, 1H), 7.16(d, *J*=2.1Hz, 1H), 7.10(dd, *J*=8.1Hz, 1.8Hz, 1H), 6.98(d, *J*=8.1Hz, 1H), 5.16(s, 2H), 3.08-3.06(m, 1H), 2.90-0.83(m, 18H), 0.52-0.48(m, 2H), 0.097-0.081(m, 2H). ¹³CNMR(75Hz, CDCl₃): 157.5, 141.4, 136.7, 133.5, 128.2, 118.8, 118.1, 59.8, 55.6, 45.6, 44.9, 41.7, 37.7, 36.4, 26.7, 26.5, 24.1, 22.1, 9.2, 4.0, 3.6. Anal. Calcd(C₂₁H₂₉N₃O·0.25H₂O): C 73.33, H 8.64, N 12.22. Found: C 73.34, H 8.66, N 11.78

4.1.10. N- cyclobutylmethylmorphinan-3-amino-urea (12)—White foam-solid (Yield 63.0 %). Mp.115–117°C. ¹HNMR(300Hz, CDCl₃): 7.14-7.02(m, 4H), 4.95(s, 2H), 2.98(d, *J*=18.3Hz, 1H), 2.80(d, *J*=3.0Hz, 1H), 2.60-1.03(m, 23H). ¹³CNMR(75Hz, CDCl₃): 157.3, 141.8, 136.4, 134.3, 128.5, 119.5, 118.9, 61.4, 55.8, 45.7, 44.9, 41.8, 37.6, 36.5, 34.8, 27.8, 26.8, 26.5, 24.4, 22.2, 18.8, 14.1. Anal. Calcd(C₂₂H₃₁N₃O·0.2H₂O): C 73.99, H 8.86, N 11.77. Found: C 73.96, H 8.85, N 11.67.

4.1.11. 3- Methylurea -N- cyclobutylmethylmorphinan (13)—3-amino-N-cyclobutylmethylmorphinan **4** (90.5 mg, 0.34mmol) was dissolved in anhydrous THF (10 ml), and a piece of Na metal was added. The mixture was stirred at room temperature for 1 min and then the methyl isocyanate (37.5mg) was added. The reaction mixture was continuously stirred at room temperature and monitored by TLC. When 3-amino-n-cyclobutylmethylmorphinan had virtually disappeared, 1mL H₂O was added to destroy any remaining trace of unreacted isocyanate. The reaction mixture was diluted into 20 mL of Et₂O and washed with NaOH aqueous solution (approximately 5% concentration) followed by brine. The ether solution was dried over MgSO₄, with stirring, and then filtered to obtain a clear ether solution of the product. Evaporation of ether provided the crude compound which was purified by column chromatography (SiO₂, EtOAc: Et₃N=100: 1) to get product as light-yellow solid (Yield 78.6%). Mp. 207–209°C. ¹HNMR(300Hz, CD₃OD): 7.20(d, *J*=2.1Hz, 1H), 7.05(dd, *J*=8.4Hz, 2.1Hz, 1H), 6.94(d, *J*=8.1Hz, 1H), 3.23-3.21(m, 1H), 2.95(d, *J*=18.6Hz, 1H), 2.82-2.79(m, 1H), 2.66(s, 3H), 2.60-1.01(m, 24H). ¹³CNMR(75Hz, CD₃OD): 159.3, 141.5, 139.4, 132.5, 129.1, 118.6, 117.5, 62.2, 57.2, 47.1, 45.7, 42.3, 38.6, 37.6, 35.6, 29.1, 28.9, 28.0, 27.7, 26.9, 25.1, 23.3, 19.6. Anal. Calcd(C₂₃H₃₃N₃O·0.2H₂O): C 74.43, H 9.07, N11.32. Found: C 74.12, H 9.07, N 11.32.

4.1.12. 3- Methylurea -N- cyclopropylmethylmorphinan (14)—light-yellow solid (Yield 66.5%). Mp.212–215°C. ¹HNMR(300Hz, CD₃OD): 7.16(s, 1H), 7.03(s, 1H), 6.66(s, 1H), 4.99-4.98(d, *J*=4.8Hz, 1H), 3.10-3.07(m, 1H), 2.93(d, *J*=18.6Hz, 1H), 2.80(s, 3H), 2.72-0.84(m, 18H), 0.53-0.49(m, 2H), 0.12-0.11(m, 2H). ¹³CNMR(75Hz, CD₃OD): 157.1, 141.8, 136.5, 134.0, 128.4, 119.5, 119.0, 60.0, 55.7, 45.7, 45.0, 41.9, 37.8, 36.5, 27.0, 26.8, 26.6, 24.2, 22.2, 9.41, 4.0, 3.6. Anal. Calcd(C₂₂H₃₁N₃O·0.2H₂O): C 73.99, H 8.86, N 11.77. Found: C 74.17, H 8.75, N 11.66.

4.2 Opioid Binding to the Human μ , δ and κ Opioid Receptors

Chinese hamster ovary (CHO) cells stably transfected with the human κ opioid receptor (hKOR-CHO), δ -opioid receptor (hDOR-CHO) were obtained from Dr. Larry Toll (SRI International, Palo Alto, CA), and the μ -opioid receptor (hMOR-CHO) were obtained from Dr. George Uhl (NIDA Intramural Program, Baltimore, MD). The cells were grown in 100 mm dishes in Dulbecco's modified Eagle's media(DMEM)supplemented with 10% fetal bovine serum(FBS) and penicillin-streptomycin (10,000 units/mL) at 37°C in a 5% CO₂ atmosphere. The affinity and selectivity of the compounds for the multiple opioid receptors were determined by incubating the membranes with radiolabeled ligands and 12 different concentrations of the compounds at 25°C in a final volume of 1mL of 50 mM Tris-HCl, pH 7.5. Incubation times of 60 min were used for the μ -selective peptide [³H]DAMGO and the κ -selective ligand [³H]U69,593. A 3-h incubation was used with the δ -selective antagonist [³H]naltrindole.

4.3 [³⁵S]GTP γ S Binding Studies To Measure Coupling to G Proteins

Membranes from CHO cells stably expressing either the human κ or μ opioid receptor were used in the experiments. Cells were scraped from tissue culture plates and then centrifuged at 1000g for 10 min at 4°C. The cells were resuspended in phosphate-buffered saline, pH 7.4, containing 0.04% EDTA. After centrifugation at 1000g for 10 min at 4°C, the cell pellet was

resuspended in membrane buffer, which consisted of 50 mM Tris-HCl, 3 mM MgCl₂, and 1 mM EGTA, pH 7.4. The membranes were homogenized by with a Dounce homogenizer, followed by centrifugation at 40000g for 20 min at 4°C. The membrane pellet was resuspended in membrane buffer, and the centrifugation step was repeated. The membranes were then resuspended in assay buffer, which consisted of 50 mM Tris-HCl, 3 mM MgCl₂, 100 mM NaCl, and 0.2 mM EGTA, pH 7.4. The protein concentration was determined by the Bradford assay using bovine serum albumin as the standard. The membranes were frozen at -80°C until used.

CHO cell membranes expressing either the human κ opioid receptor (15 μ g of protein per tube) or μ opioid receptor (7.5 μ g of protein per tube) were incubated with 12 different concentrations of the agonist in assay buffer for 60 min at 30°C in a final volume of 0.5 mL. The reaction mixture contained 3 μ M GDP and 80 pmol of [³⁵S]GTP γ S. Basal activity was determined in the presence of 3 μ M GDP and in the absence of an agonist, and nonspecific binding was determined in the presence of 10 μ M unlabeled GTP γ S. Then, the membranes were filtered onto glass fiber filters by vacuum filtration, followed by three washes with 3 mL of ice-cold 50 mM Tris-HCl, pH 7.5. Samples were counted in 2 mL of Ecoscint A scintillation fluid. Data represent the percent of agonist-stimulation [³⁵S]GTP γ S binding over the basal activity, defined as [(specific binding/basal binding) $\times$ 100] - 100. All experiments were repeated at least three times and were performed in triplicate. To determine antagonist activity of a compound at the μ opioid receptors, CHO membranes expressing the μ opioid receptor were incubated with the compound in the presence of 200 nM of the agonist DAMGO. To determine antagonist activity of a compound at the κ opioid receptors, CHO membranes expressing the κ opioid receptor were incubated with the compound in the presence of 100 nM of the κ agonist U50,488.

Acknowledgments

This work was supported by the National Institute on Drug Abuse:RO1-DA14251(JLN) AND KO5DA00360 (JMB). Levorphanol tartrate was generously donated by Mallinckrodt Inc

References and notes

1. Aldrich, JV. Nartotic Analgesics. In: Abraham, DJ., editor. Burger's Medicinal Chemistry & Drug Discovery. Vol. 6. Press: John Wiley & Sons, Inc; 2003. p. 329-481.
2. Dhawan DN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M. Pharmacol Rev 1996;48:567. [PubMed: 8981566]
3. Pert C, Snyder S. Science 1973;179:1011. [PubMed: 4687585]
4. Fries, DS. Opioid analgesics. In: Foye, WO.; Lemke, TL.; Williams, DA., editors. Principles of Medicinal Chemistry. Williams & Wilkins; 1995. p. 453-479.
5. Zhang A, Xiong W, Hilbert JE, DeVita EK, Bidlack JM, Neumeyer JL. J Med Chem 2004;47:1886. [PubMed: 15055988]
6. Zhang A, Van Vliet S, Neumeyer JL. Tetrahedron Lett 2003;44:6459.
7. Neumeyer JL, Bidlack JM, Zong R, Bakthavachalam V, Gao P, Cohen DJ, Negus SS, Mello NK. J Med Chem 2000;43:114. [PubMed: 10633042]
8. Neumeyer JL, Gu XH, Van Vliet LA, DeNunzio NJ, Rusovici DE, Cohen DJ, Negus SS, Mello NK, Bidlack JM. Bioorg Med Chem Lett 2001;11:3049. [PubMed: 11714608]
9. Wentland MP, Sun X, Bu Y, Lou R, Cohen DJ, Bidlack JM. Bioorg Med Chem Lett 2005;15:2547. [PubMed: 15863314]
10. Olfoson RA, Marts JT, Seret JP, Piteau M, Malfroot TA. J Org Chem 1984;49:2081.
11. Wu Y, Limburg DC, Wilkinson DE, Hamilton G. Journal of Heterocyclic Chemistry 2003;40:191.
12. Wu W, Burnett DA, Spring R, Greenlee WJ, Smith M, Favreau L, Fawzi A, Zhang H, Lachowicz JE. J Med Chem 2005;48:680. [PubMed: 15689153]

13. Venuti MC, Stephenson RA, Alvarez R, Bruno JJ, Strosbery AM. J Med Chem 1988;31:2136. [PubMed: 2846839]

Figure 1.

Figure 2.

Figure 3.
3-D structures of compounds **7** & **5**

Conditions: (a) $\text{HNO}_3/\text{CH}_3\text{COOH}$, (b) Pd/C , H_2 , (c) THF, Di(imidazole-1-yl)methanimine (d) THF, 1, 1'-Carbonyl-diimidazole

Scheme 1.
Synthesis of Oxazol analogs

Table 1
***K_i* Values For The Inhibition of μ , δ and κ Opioid Binding to Chinese Hamster Ovary Membrane by Novel Opioids**

Compound	<i>K_i</i> $\pm$ SEM(nM)		
	[³ H]DAMGO(μ)	[³ H]U69,593(κ)	[³ H]Naltrindole(δ)
1(cyclorphan)	0.062 $\pm$ 0.003	0.034 $\pm$ 0.002	1.9 $\pm$ 0.072
2(butorphan)	0.23 $\pm$ 0.01	0.079 $\pm$ 0.003	5.9 $\pm$ 0.55
3(MCL-149)	1.3 $\pm$ 0.029	0.18 $\pm$ 0.003	150 $\pm$ 2.0
4(MCL-182)	3.7 $\pm$ 0.26	1.8 $\pm$ 0.06	180 $\pm$ 85
5 (MCL-147) ATPM	1.5 $\pm$ 0.2	0.049 $\pm$ 0.005	29 $\pm$ 2
6 (MCL-183) ATBM	7.1 $\pm$ 0.5	0.79 $\pm$ 0.02	230 $\pm$ 21
7(MCL-453)	150 $\pm$ 5.1	52 $\pm$ 1.0	18% inh@10 μ M
8(MCL-454)	40 $\pm$ 1.7	6.6 $\pm$ 0.27	46% inh@10 μ M
9(MCL-457)	160 $\pm$ 21	47 $\pm$ 1.6	44% inh@10 μ M
10(MCL-458)	5.8 $\pm$ 0.56	1.9 $\pm$ 0.057	360 $\pm$ 10
11(MCL-448)	1.4 $\pm$ 0.032	0.61 $\pm$ 0.015	23 $\pm$ 2.9
12(MCL-447)	3.2 $\pm$ 0.17	8.9 $\pm$ 1.1	160 $\pm$ 19
13(MCL-446)	12 $\pm$ 0.90	2.3 $\pm$ 0.045	50 $\pm$ 2.0
14(MCL-445)	22 $\pm$ 1.0	20 $\pm$ 0.19	270 $\pm$ 7.4

Table 2
Agonist and Antagonist Properties of Compounds in Stimulating [³⁵S]GTPγS Binding Mediated by the κ Opioid Receptor^a

Compound	Pharmacological properties	$E_{\max}$ (%maximal stimulation)	EC ₅₀ (nM)	$I_{\max}$ (%maximal inhibition)
(-)-U50,488	agonist	110 ± 2.0	46 ± 16	---
1 (cyclophphan)	agonist	90 ± 10	0.19 ± 0.04	---
2 (butorphan)	agonist	80 ± 6.8	1.3 ± 0.4	---
5^b (MCL-147)ATPM	agonist	80 ± 6	2.4 ± 0.6	---
6^b (MCL-183)ATBM	agonist	80 ± 1	29 ± 4	---
13 (MCL-446)	agonist	67 ± 5.5	84 ± 8.1	No effect
12 (MCL-447)	agonist	64 ± 2.0	87 ± 10	No effect
11 (MCL-448)	agonist	84 ± 7.6	33 ± 2.3	No effect

^a Membranes from CHO cells that stably expressed only the κ opioid receptor were incubated with varying concentrations of the compounds. The stimulation of [³⁵S]GTPγS binding was measured as described in the Experimental Section. To determine the antagonist properties of a compound, membranes were incubated with 100 nM of the κ agonist U50,488 in the presence of varying concentrations of the compound. The $I_{\max}$ value is the maximal percent inhibition obtained with the compound. Dashed lines indicate that the compound was not tested for antagonist properties because of its high $E_{\max}$ value.

^b . Data from Ref. 5

Table 3
Agonist and Antagonist Properties of Urea Compounds in Stimulating [³⁵S]GTPγS Binding Mediated by the μ Opioid Receptor^a

compound	Pharmacological properties	<i>E</i> _{max} (% maximal stimulation)	EC ₅₀ (nM)	<i>I</i> _{max} (% maximal inhibition)	IC ₅₀ (nM)
DAMGO	agonist	120 ± 12	110 ± 9.0	---	---
1 (cyclophphan)	partial agonist	40 ± 2.9	0.80 ± 0.06	50 ± 1	1.7 ± 0.4
2 (butorphan)	partial agonist	50 ± 2.5	1.6 ± 0.2	50 ± 3	20 ± 3
12 (MCL-447)	partial agonist	33 ± 1.5	63 ± 4.6	35 ± 1.6	1500 ± 300
11 (MCL-448)	partial agonist	21 ± 0.70	31 ± 9.2	52 ± 3.6	380 ± 86

^a Membranes from CHO cells that stably expressed the μ opioid receptor were incubated with varying concentrations of the compounds. The stimulation of [³⁵S]GTPγS binding was measured as described in the Experimental Section. EC₅₀ values were the concentration of compound needed to produce 50% of the *E*_{max} value. To determine the antagonist properties of a compound, membranes were incubated with 200 nM of the μ agonist DAMGO in the presence of varying concentrations of the compound. The *I*_{max} value is the maximal percent inhibition obtained with the compound. The IC₅₀ value is the concentration of compound needed to produce half maximal inhibition. Dashed lines indicate that the compound was not tested.